What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Aurelie Najm AurelieRheumo
3 years 6 months ago
📲The great debate on Telemedicine 💻
R. Landewe warns us against "check box medicine" and its consequences on AxSpA overdiagnosis.
@RheumNow #EULAR2022 https://t.co/Xwg0aAdHwE
TheDaoIndex KDAO2011
3 years 6 months ago
“#SLEDAI should be scored when there is joint swelling (not just tenderness)—note that only 48% of pts with tenderness will have u/s evidence of inflammation” – Prof E Vital #EULAR2022 @rheumnow https://t.co/hhsZ9wMAWs
Robert B Chao, MD doctorRBC
3 years 6 months ago
Ok to taper?
In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o tapering.
69% of tapered group remained in LDA, 73% no-taper group in LDA after 12 months.
Taper group did use more NSAIDs, cDMARDs, steroids
@RheumNow #EULAR2022 ABST#OP0261
Janet Pope Janetbirdope
3 years 6 months ago
JAK will quiet Still’s disease? 7 w Still’s 4 refractory disease had benefit w #JAKi POS0014. Needs more data but looks promising most w partial response . 5 on #Tofacitinib and 2 w #Baricitinib. @eular_org #EULAR2022 POS0014 @RheumNow https://t.co/j9IRgT9XJf
Aurelie Najm AurelieRheumo
3 years 6 months ago
Insightful session with H Schulze-Koops: JAKi-Are all promises fulfilled?
"JAKi have not shown us sufficient data to prove that they can induce remission or inhibit disease progression"
@RheumNow #EULAR2022 https://t.co/SKKAS1ViIU
TheDaoIndex KDAO2011
3 years 6 months ago
Dr. Werth shared her evidence based algorithm for managing cutaneous lupus published here: https://t.co/RytrxLdLHK #EULAR2022 @rheumnow https://t.co/wq28btM24U
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 @ChristianDejaco: Do we need see our patient at all?
Provocative statement asking if some disease states can be evaluated, diagnosed, educated and monitored digitally.
"It's already out there!" "Should we leave it to the market" or should rheum take a lead?
@RheumNow https://t.co/iMrlKZgtbg
Richard Conway RichardPAConway
3 years 6 months ago
Casado et al. Efficacy of US guided needle fragmentation or lavage for calcific tendonitis refractory subacromial injection. Mean VAS decreased from 7.6±1.5 to 4.5±3.8 at month 4, 82.9% radiologic improvement. No control group! @RheumNow #EULAR2022 OP0289 https://t.co/KarkB7XL8u
Robert B Chao, MD doctorRBC
3 years 6 months ago
Pregnancy data in SpA from 122 pts
40% flared during pregnancy, more frequent 2nd trimester, pts w/ axial dz
7 pts required start of TNFi during 2nd or 3rd trimester
40% post-partum
@RheumNow #EULAR2022 ABST#POST0151 https://t.co/cdFRhRuCVH
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 POS0276
Xray & US for CPPD:
US: sensitivity in all sites
Xray: highly specific, low sensitivity
Combo: Best for patients with Negative Xray or Inconclusive US (only one positive site)
@Rheumnow @MymaAlbaydaMD @USSONAR_Rh
David Liew drdavidliew
3 years 6 months ago
PMR/GCA patients: should you be worried about how well your COVID vaccine worked?
Actually, post-two vaccines, pretty good Ab (&cellular) response, esp if not on MTX/PNL>10
Glad to see our PMR/GCA pts protected
@VasculitisUMCG @SleenYannick @ElisabethBrouw3 #EULAR2022 @RheumNow https://t.co/9vy0W4ojOF
Richard Conway RichardPAConway
3 years 6 months ago
Boers et al. GLORIA trial of long term 5mg pred in RA. Titled as "favourable balance of benefit and harm". I cannot agree. 24% increase adverse events, NNH 9, for DAS28 0.37 better at 1 year, and really no difference after that. @RheumNow #EULAR2022 OP0263 https://t.co/eO4f1CjH5q https://t.co/VyyZm1QvYy
Richard Conway RichardPAConway
3 years 6 months ago
Meudec et al. Comparative effects of JAKi on NK cell function on cancer cells (lymphoma and lung cancer). Tofacitinib had most negative impact. Interesting given blanket black box based on tofa data! @RheumNow #EULAR2022 OP0265 https://t.co/XSE7hP60Ui https://t.co/MjtAJcvWAD
Robert B Chao, MD doctorRBC
3 years 6 months ago
Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI.
Early changes in PsO may suggest a PsA-like MRI pattern may be present!
Is this how we predict which PsO -> PsA?
@RheumNow #EULAR2022 ABST#OP0292 https://t.co/NGfFkSqlaM
Richard Conway RichardPAConway
3 years 6 months ago
Nyam et al. JAK-pot study. >90000 treatment courses. No difference in aHR for treatment stop due to adverse events in JAKi vs TNFi or non-TNF bDMARD. @RheumNow #EULAR2022 OP0266 https://t.co/3tgADvH1Bq https://t.co/2qLRzfMB9c
Poster Hall